EMEA-002475-PIP04-23 - paediatric investigation plan

Spesolimab
PIPHuman

Key facts

Invented name
Spevigo
Active Substance
Spesolimab
Therapeutic area
Skin and subcutaneous tissue disorders
Decision number
P/0157/2024
PIP number
EMEA-002475-PIP04-23
Pharmaceutical form(s)
  • Solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of hidradenitis suppurativa
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries

Boehringer Ingelheim International GmbH

Tel. +49 6132 778271
Email: Paediatrics@boehringer-ingelheim.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page